Worldwide Emergence of Extensively Drug-resistant Tuberculosis

Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates th...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Emerging infectious diseases Ročník 13; číslo 3; s. 380 - 387
Hlavní autori: Shah, N. Sarita, Wright, Abigail, Bai, Gill-Han, Barrera, Lucia, Boulahbal, Fadila, Martín-Casabona, Nuria, Drobniewski, Francis, Gilpin, Chris, Havelková, Marta, Lepe, Rosario, Lumb, Richard, Metchock, Beverly, Portaels, Françoise, Rodrigues, Maria Filomena, Rüsch-Gerdes, Sabine, Van Deun, Armand, Vincent, Veronique, Laserson, Kayla, Wells, Charles, Cegielski, J. Peter
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States U.S. National Center for Infectious Diseases 01.03.2007
Centers for Disease Control and Prevention
Predmet:
Antitubercular Agents - pharmacology
Communicable Disease Control
Drug resistance in microorganisms
emerging
Global Health
Health aspects
Humans
infectious diseases
Laboratories
multidrug-resistant
Mycobacterium tuberculosis
Mycobacterium tuberculosis - drug effects
Public health
second-line drugs
Sentinel Surveillance
tuberculosis
Tuberculosis - drug therapy
Tuberculosis - microbiology
Tuberculosis - prevention & control
Tuberculosis, Multidrug-Resistant
United States
Switzerland
ISSN:1080-6040, 1080-6059
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Mycobacterium tuberculosis strains that are resistant to an increasing number of second-line drugs used to treat multidrug-resistant tuberculosis (MDR TB) are becoming a threat to public health worldwide. We surveyed the Network of Supranational Reference Laboratories for M. tuberculosis isolates that were resistant to second-line anti-TB drugs during 2000-2004. We defined extensively drug-resistant TB (XDR TB) as MDR TB with further resistance to > or = 3 of the 6 classes of second-line drugs. Of 23 eligible laboratories, 14 (61%) contributed data on 17,690 isolates, which reflected drug susceptibility results from 48 countries. Of 3,520 (19.9%) MDR TB isolates, 347 (9.9%) met criteria for XDR TB. Further investigation of population-based trends and expanded efforts to prevent drug resistance and effectively treat patients with MDR TB are crucial for protection of public health and control of TB.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1080-6040
1080-6059
DOI:10.3201/eid1303.061400